Clearmind Medicine (CSE: CMND) (FSE: CWY0), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announced that professors Wim van den Brink and Gabriele Fischer have joined the company’s scientific advisory board. According to the update, van den Brink, M.D., Ph.D., is a professor of addiction psychiatry at the Academic Medical Center of the University of Amsterdam and a recognized expert in the neurobiology and pharmacological treatment of substance use disorders and behavioral addictions. Gabriele Fischer, M.D., is a professor of addiction research and treatment, medical director of the Addiction Clinic at the Department of Psychiatry and Psychotherapy at the Medical University of Vienna, and has acted as principle or cooperating investigator on international epidemiological clinical and psychopharmacological studies in the field of substance use disorder and nonsubstance-related addictions. “Professor van den Brink and Professor Fischer have both made substantial contributions to the field of substance abuse and related behaviors, advancing the way we understand and treat addiction,” said Adi Zuloff-Shani, Ph.D., CEO of Clearmind, of the appointments. “There are few scientists in the world with their breadth of knowledge and experience, and we are delighted to welcome them to our scientific advisory board.”
To view the full press release, visit https://ibn.fm/lo09v
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The company’s intellectual portfolio currently consists of two patent families. The first, “Binge Behavior Regulators,” has been granted in the U.S., Europe, China and India, with pending divisional applications in Europe and the U.S. The second, “Alcohol Beverage Substitute,” has been approved for a European patent, with pending applications in the U.S., China and India. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol CMND and the Frankfurt Stock Exchange under the symbol CWY0. For more information about the company, visit www.ClearmindMedicine.com.
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire is part of the InvestorBrandNetwork.